Capital Com MENA Securities Trading LLC is regulated by the Capital Market Authority.
Open platformOpen platform

Organon’s VTAMA shows consistent efficacy across atopic dermatitis subgroups in pooled Phase 3 analysis

By Public Technologies
  • Organon will present a pooled post-hoc analysis of Phase 3 VTAMA cream trials at ACAAI on Nov. 14, 2026.
  • The trials enrolled 813 adults and children aged 2 and older with moderate to severe atopic dermatitis.
  • VTAMA improved disease severity and itch versus vehicle across evaluated patient subgroups, with benefits appearing within one week and lasting through eight weeks.
  • The nonsteroidal topical treatment was well tolerated; common adverse events included folliculitis, headache and respiratory infections.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Organon & Co. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261112109975) on November 12, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.